Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study evaluated a UV-Vis spectrophotometric method to measure minoxidil in compounded capsules from pharmacies in Pernambuco, Brazil, finding that while the formulations met weight criteria, most deviated significantly from declared minoxidil content, highlighting the need for robust quality control in compounded medicines.

This study concluded that Gushen Shengfa pills combined with Wuling capsules improved sleep quality and hair growth more effectively than compound glycyrrhizin and cystine tablets in patients with alopecia areata.

In this study, researchers reported that hardshell capsules using the DiluCap® line of excipients demonstrated varying dissolution profiles under gastrointestinal-simulating conditions, with minoxidil and finasteride showing rapid release and melatonin and naltrexone displaying controlled release, indicating their suitability for different applications in compounding pharmacies.

This study found that minoxidil inhibited lens epithelial cell migration, proliferation, and collagen secretion in vitro, suggesting it may help prevent postoperative capsular opacification.

This study found that a once-daily capsule of minoxidil and spironolactone may safely reduce hair loss severity in women with female pattern hair loss.

This study reported that once-daily treatment with oral minoxidil and spironolactone for 12 months reduced hair loss severity and hair shedding in women with pattern hair loss, with generally mild side effects, though results came from an uncontrolled, observational pilot study.

This study identified a new minoxidil analogue called triaminodil in an illegal hair-growth supplement, but no data on its chemical, toxicological, or pharmacological properties are available yet.

In this report, the author summarized activities from a six-month internship in community and hospital pharmacy settings, exploring topics like skin microbiome health implications and advancements in antiviral therapy for Hepatitis B and D, highlighting the pharmacist's role in patient care and innovative treatments.

This study developed a validated method to detect prohibited drugs in dietary supplements, finding minoxidil, triaminodil, and finasteride in some samples.

This study found that combination therapy involving Minoxidil, Finasteride, or Saw palmetto with a dermaroller showed good to excellent results in male pattern baldness and moderate response in female pattern baldness over six months.

This report presents a case of cicatricial female pattern hair loss in a 36-year-old woman, treated with topical minoxidil, tacrolimus, clobetasol, and oral medications, resulting in stabilized hair loss over six months.

This study validated a new RP-HPLC method for accurately determining doxazosin mesylate and finasteride in bulk powders and capsule formulations.

This study found that a dutasteride tablet formulation using cyclodextrin complex, solubilizing polymer, and surfactant achieved similar bioavailability in beagle dogs to that of a commercial capsule.

This study introduces the term "hair matrix cyst" for a cyst with both pilomatricoma and epidermal cyst characteristics, highlighting its potential for misdiagnosis among similar skin conditions.

In this study, oral minoxidil combined with other medications improved blood pressure control in patients with severe hypertension but often had to be discontinued due to side effects.

This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.

This study found that topical minoxidil can be effective in preventing flap necrosis during latissimus dorsi flap reconstruction in patients who have undergone neoadjuvant chemoradiation.

This study reviewed the literature on low-dose oral minoxidil as a primary treatment for various hair loss disorders, concluding that it is a successful and well-tolerated alternative to topical minoxidil for patients with poor adherence to other therapies.

This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.

This study found that a once-daily 5% minoxidil topical foam is as effective as a twice-daily 2% minoxidil topical solution for hair growth in women with androgenetic alopecia, with fewer side effects and greater styling convenience.

This paper discusses the pathogenesis of cardiovascular lesions in dogs associated with minoxidil, noting that lesions were not prevented by adrenergic blockade or neural activity suppression, and highlights the differences in injury progression between coronary arteries and the right atrium.

Minoxidil can cause heart muscle damage in dogs.

This study concluded that a combined once-daily solution of 5% minoxidil and 0.01% tretinoin is as effective and safe as the conventional twice-daily 5% minoxidil application for treating androgenetic alopecia in men.

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

Minoxidil lowers blood pressure, increases heart rate, and improves blood flow in dogs.

Minoxidil may cause heart issues in animals and humans.

This study observed that minoxidil induced myocardial necroses and hemorrhages in beagle dogs and miniature swine, with greater severity seen in dogs.

Minoxidil lowers blood pressure more effectively but has more side effects, so try hydralazine first.

This study found that using very-low-dose oral minoxidil (0.25 mg/d) led to improvement or stabilization of hair parameters in 40% to 60% of men with androgenetic alopecia, although results were not statistically significant for the overall group.

These drugs cause hair growth without affecting testosterone or adrenal hormones.